Risk of relapse after natalizumab withdrawal
Results from the French TYSEDMUS cohort
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 8, 2016
- Accepted in final form September 23, 2016
- First Published October 28, 2016.
Author Disclosures
- Caroline Papeix, MD*,
- Sandra Vukusic, MD, PhD*,
- Romain Casey, PhD,
- Nadine Debard,
- Bruno Stankoff, MD, PhD,
- Serge Mrejen, MD,
- Zoe Uhry,
- Eric Van Ganse, MD, PhD,
- Anne Castot, PhD,
- Michel Clanet, MD, PhD,
- Catherine Lubetzki, MD, PhD‡,
- Christian Confavreux, MD, PhD†,‡;
- For the TYSEDMUS and OFSEP Group
- Caroline Papeix, MD*,
bayer sherring novartis teva
NONE
NONE
NONE
NONE
NONE
educational activities : bayer sherring (2010), biogen idec (2005-2014), novartis (2009-2015), sanofi genzyme (2008-2015), Merk serono (2009-2012) Roche (2009-2015)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sandra Vukusic, MD, PhD*,
Biogen-Idec, Geneuro, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma
NONE
Biogen-Idec, Geneuro, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma
NONE
NONE
NONE
NONE
Consultancy in board for Biogen-Idec, Geneuro, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma
NONE
NONE
NONE
Biogen-Idec, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma
Biogen-Idec, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Romain Casey, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nadine Debard,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bruno Stankoff, MD, PhD,
advisory boards for Biogen Idec, Novartis, Genzyme, Teva-Pharma and Roche
NONE
travel: EAN 2015 by TEVA, ECTRIMS 2016 by NOVARTIS lectures for TEVA, BIOGEN, NOVARTIS, GENZYME
NONE
Patent pending for the identification of a compound that stimulate demyelination
NONE
NONE
NONE
NONE
NONE
NONE
research support from Merck-Serono and genzyme
NONE
research support from ANR (agence nationale de la recherche), PHRC (programme hospitalier de recherche clinique), fondation ARSEP and Progressive MS alliance
grants from ARSEP fondation (association d e recherche sur la sclerose en plaques)
NONE
NONE
NONE
NONE
NONE
NONE
- Serge Mrejen, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Zoe Uhry,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eric Van Ganse, MD, PhD,
Dr. Van Ganse reports grants and personal fees from ALK ABELLO, personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from BMS, personal fees from Boehringer Ingelheim, grants and personal fees from GlaxoSmithKline, personal fees from IMS, personal fees from LASER, grants and personal fees from Merck Sharp and Dohme, outside the submitted work; .
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Van Ganse reports grants and personal fees from ALK ABELLO, personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from BMS, personal fees from Boehringer Ingelheim, grants and personal fees from GlaxoSmithKline, personal fees from IMS, personal fees from LASER, grants and personal fees from Merck Sharp and Dohme, outside the submitted work; .
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anne Castot, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michel Clanet, MD, PhD,
Biogenidec; Genzyme, Merck Serono, Sanofi, Teva
NONE
ECTRIMS travel for annual meetings
Multiple Sclerosis Journal without compensation until 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
ARSEP ( Foundation for research in Multiple Sclerosis) EDMUS Eugene DEVIC Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Catherine Lubetzki, MD, PhD‡,
VERTEX , BIOGEN, NOVARTIS, GENZYME
NONE
NONE
Associate editor BRAIN editorial board member of MSJ and MSJ and related disorders
NONE
NONE
NONE
BIOGEN, ROCHE, GENZYME
NONE
scientific collaboration with EMD SERONO
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Confavreux, MD, PhD†,‡;
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- For the TYSEDMUS and OFSEP Group
- From the Neurology Department (C.P., S.M., C.L.), Pitié-Salpêtrière Hospital, Paris; Service de Neurologie A, Hôpital Neurologique Pierre Wertheimer (S.V., C.C.), and Neuro-epidemiology and Pharmaco-epidemiology (E.V.G.), Hospices Civils de Lyon, Lyon/Bron; Centre des Neurosciences de Lyon (S.V., C.C.), INSERM 1028 et CNRS UMR5292, Equipe Neuro-oncologie et Neuro-inflammation; Université de Lyon (S.V., C.C.); Observatoire Français de la Sclérose en Plaques (R.C., N.D., Z.U.), Bron; Neurology Department (B.S.), Saint Antoine Hospital, Paris; Agence Nationale de Sécurité des Médicaments (ANSM, formerly Agence Française de Sécurité Sanitaire des Produits de Santé—AFSSAPS) (A.C.), Saint-Denis; and Neurology Department (M.C.), Purpan Hospital, Toulouse, France.
- Correspondence to Dr. Papeix: caroline.papeix{at}psl.aphp.fr
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Fingolimod after natalizumab and the risk of short-term relapseVilija G. Jokubaitis, Vivien Li, Tomas Kalincik et al.Neurology, March 07, 2014 -
Article
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS StudyPaul O'Connor, Andrew Goodman, Ludwig Kappos et al.Neurology, June 04, 2014 -
Article
Pregnancy decision-making in women with multiple sclerosis treated with natalizumabII: Maternal risksEmilio Portaccio, Lucia Moiola, Vittorio Martinelli et al.Neurology, February 07, 2018 -
Research
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis et al.Neurology: Clinical Practice, March 21, 2016